A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
Novartis prevailed in the latest court battle over jawbone injuries in Zometa patients. The company did properly warn patients about the drug's risks, a New Jersey jury determined after a 13-day trial.
Novartis is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict on plaintiff Beverly Meng's claims that the Swiss drugmaker downplayed the bone drug's risks.
The India-based generics maker pleaded guilty to U.S. drug safety violations and agreed to pay $500 million in penalties, in the largest-ever federal settlement with a maker of copycat drugs.
PharmaSecure has expanded rapidly as the pharma industry seeks to authenticate its goods amid out-of-control counterfeiting. Patients might have the most at stake in verification of medicines, with fake drugs blamed for killing thousands of people annually.
Johnson & Johnson has been negotiating terms of a multibillion dollar settlement over aggressive marketing of its antipsychotic drug Risperdal with federal authorities for at least two years, and now it is hung on talk over breasts, The Wall Street Journal says.
Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.
The popular Z-Pak antibiotic, linked to heart-rhythm problems in March, may not be risky for the average patient, a new study suggests.
The $6.5 million jury verdict in Takeda Pharmaceuticals' first Actos trial didn't last long. Judge Kenneth Freeman tossed out the jury's judgment, saying that plaintiffs' lawyers didn't prove that Jack Cooper's bladder cancer was linked to his use of Actos.
The jury in the latest Fosamax trial has spoken, and it spoke for Merck. In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's broken leg wasn't caused by the bone drug Fosamax. It was the first jury verdict among the more than 3,000 lawsuits claiming Fosamax caused serious femur fractures.